Incorporating predictions of individual patient risk in clinical trials

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 4, 2004, Pages 348-352

  Kattan, Michael W ^a   Vickers, Andrew J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Case mix; Nomogram; Power; Sample size

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CONFERENCE PAPER; DECISION MAKING; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; KIDNEY CANCER; MENSTRUAL CYCLE; ONSET AGE; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE CANCER; RECURRENCE RISK; RISK FACTOR; SAMPLE SIZE; SARCOMA; SEX DIFFERENTIATION; SMOKING; STATISTICAL MODEL; STOMACH CANCER;

CLINICAL TRIALS, PHASE III; CONTROL GROUPS; DIAGNOSIS-RELATED GROUPS; HUMANS; MODELS, STATISTICAL; NEOPLASMS; PATIENT SELECTION; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 3342881158     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2004.04.012     Document Type: Conference Paper

References (16)

1. Bach P.B., Kattan M.W., Thornquist M.D., et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 95:2003;470-478
2. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 81:1989;1879-1886
3. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer a multi-institutional pooled analysis. JAMA. 281:1999;1598-1604
4. Kattan M.W., Zelefsky M.J., Kupelian P.A., Scardino P.T., Fuks Z., Leibel S.A. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 18:2000;3352-3359
5. Kattan M.W., Karpeh M.S., Mazumdar M., Brennan M.F. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 21:2003;3647-3650
6. 1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 21:2003;3573-3579
7. Kattan M.W., Giri D., Hummer A., et al. A nomogram predicting 15-year breast cancer survival in women with negative auxiliary lymph nodes (ALNS) by routine histopathologic analysis and without adjuvant therapy. Proc Am Soc Clin Oncol. 22:2003;872. [abstract]
8. Kattan M.W., Leung D.H.Y., Brennan M.F. A postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 20:2002;791-796
9. Brennan, MF, Kattan, MW. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg [in press].
10. Kattan M.W., Reuter V., Motzer R.J., Katz J., Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 166:2001;63-67
11. Kattan M.W. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients preoperative application in prostate cancer. Curr Opin Urol. 13:2003;111-116
12. Rivera E., Valero V., Arun B., et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 21:2003;3249-3254
13. Bajorin D. The Phase III candidate Can we improve the science of selection? J Clin Oncol. 22:2004;211-213
14. Mazumdar M., Fazzari M., Panageas K.S. A standardization method to adjust for the effect of patient selection in phase II clinical trials. Stat Med. 20:2001;883-892
15. Solit D.B., Morris M., Slovin S., et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 98:2003;842-848
16. Glasziou P.P., Irwig L.M. An evidence-based approach to individualizing treatment. BMJ. 311:1995;1356-1359